ClinicalTrials.gg
CompletedNCT00987727Updated Sep 21, 2011Results posted

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

A Phase 4 interventional study of carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) and sodium hyaluronate 0.18% (VISMED® Multi) in Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Allergan. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-21.

Primary conditionKeratoconjunctivitis SiccaRegistry: Dry Eye SyndromesReclassifiedWhy we changed it
Registry
Dry Eye Syndromes — the first condition term the registry derived for this study.
ClinicalTrials.gg
Keratoconjunctivitis Sicca
Why
  1. The study's listed conditions name Keratoconjunctivitis Sicca, a narrower term within Dry Eye Syndromes.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

02

Conditions studied

  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Browse trials for

03

In context

Keratoconjunctivitis Sicca Reclassified

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

This study's enrollment of 82 is close to the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.

Browse Keratoconjunctivitis Sicca studies →

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Compared within Keratoconjunctivitis Sicca, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dry Eye Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been using artificial tears for at least 3 months prior to study inclusion
  • Have been using preservative free artificial tears at least three times daily (TIB) for at least 2 weeks immediately prior to study inclusion
  • Having moderate to severe symptoms suggestive of dry eye

Exclusion criteria

Exclusion Criteria:

  • Current enrollment in an drug or device study or participation in such a study within 3 months prior to entry into this study
  • Moderate to severe blepharitis
  • History or active signs of ocular trauma, ocular infection, or ocular inflammation within the last 3 months
  • History or active signs of ocular allergic disease or ocular herpes within the last year
  • History or active signs of severe or serious ocular conditions such as inflammatory corneal ulcers, recurrent erosions, and uveitis at any time.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    1

    carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)

    Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)

  • Active comparator
    2

    sodium hyaluronate 0.18% (VISMED® Multi)

    Drug: sodium hyaluronate 0.18% (VISMED® Multi)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Global Ocular Staining Score at Day 35

    Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).

    Time frame: Baseline, Day 35

Secondary outcomes

  1. Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35

    Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.

    Time frame: Baseline, Day 35

07

Results

Posted Sep 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneCarboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)Sodium Hyaluronate 0.18% (VISMED® Multi)
Started4141
Completed3634
Not completed57

Outcome measures

PrimaryChange From Baseline in Global Ocular Staining Score at Day 35

Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).

Time frame:
Baseline, Day 35
Reported as:
Mean · Number on a scale (score)
Change From Baseline in Global Ocular Staining Score at Day 35
Number on a scale (score)Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)Sodium Hyaluronate 0.18% (VISMED® Multi)
Baseline5.4 ± 1.595.9 ± 1.47
Day 35-1.8 ± 1.95-1.8 ± 2.30
SecondaryChange From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35

Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.

Time frame:
Baseline, Day 35
Reported as:
Mean · Number on a scale (score)
Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35
Number on a scale (score)Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)Sodium Hyaluronate 0.18% (VISMED® Multi)
Baseline49.05 ± 17.06051.98 ± 18.164
Day 35-13.58 ± 19.047-13.66 ± 16.542

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)—1/41 (2.4%)0/41 (0%)
Sodium Hyaluronate 0.18% (VISMED® Multi)—1/38 (2.6%)0/38 (0%)
Most frequent serious events
Most frequent serious events
EventCarboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)Sodium Hyaluronate 0.18% (VISMED® Multi)
Amyotrophic Lateral SclerosisNervous system disorders0/411/38
Upper Limb FractureInjury, poisoning and procedural complications1/410/38

Baseline characteristics

Age, Customized
Age, Customized(participants)Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)Sodium Hyaluronate 0.18% (VISMED® Multi)Total
<65 years222951
>=65 years191231
Sex: Female, Male
Sex: Female, Male(Participants)Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)Sodium Hyaluronate 0.18% (VISMED® Multi)Total
Female363874
Male538
08

Study locations

1 site
  • Paris, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jul 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2009
First posted
Oct 1, 2009
Start
Nov 2009
Primary completionActual
Jul 2010
CompletionActual
Sep 2010
Results first posted
Sep 21, 2011
Last update
Sep 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00987727
Lead sponsor
Allergan
First posted
Oct 1, 2009
Start date
Nov 2009
Primary completion
Jul 2010
Completion
Sep 2010
Results posted
Sep 21, 2011
Last update
Sep 21, 2011

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carboxymethylcellulose

Start the discussion